SSB 4
Alternative Names: SSB-4Latest Information Update: 15 Feb 2024
Price :
$50 *
At a glance
- Originator AB Biosciences
- Class Antivirals
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase Unknown COVID 2019 infections
Most Recent Events
- 08 Feb 2024 SSB 4 is available for licensing as of 08 Feb 2024. https://abbiosciences.com/pages/ssb-4
- 08 Feb 2024 Investigations in COVID-2019 infections in USA (Parenteral), prior to February 2024 (AB Biosciences pipeline, February 2024)